A Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Pretreated Metastatic Triple Negative Breast Cancer
What is the purpose of this trial?
This study will investigate the safety and efficacy of TIL therapy in patients with metastatic TNBC who have progressed on at least one and no more than three prior systemic anticancer therapies.
- Trial withYale Cancer Center
- Start Date12/22/2019
- End Date12/31/2021
- Last Updated06/01/2020
- Study HIC#2000025837